Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
KPTI

KPTI - Karyopharm Therapeutics Inc Stock Price, Fair Value and News

1.02USD-0.01 (-0.97%)Market Closed

Market Summary

KPTI
USD1.02-0.01
Market Closed
-0.97%

KPTI Alerts

  • 1 major insider sales recently.

KPTI Stock Price

View Fullscreen

KPTI RSI Chart

KPTI Valuation

Market Cap

120.1M

Price/Earnings (Trailing)

-0.82

Price/Sales (Trailing)

0.85

EV/EBITDA

-0.73

Price/Free Cashflow

-1.02

KPTI Price/Sales (Trailing)

KPTI Profitability

EBT Margin

-103.94%

Return on Equity

86.61%

Return on Assets

-71.57%

Free Cashflow Yield

-98.06%

KPTI Fundamentals

KPTI Revenue

Revenue (TTM)

140.5M

Rev. Growth (Yr)

-14.4%

Rev. Growth (Qtr)

-1.84%

KPTI Earnings

Earnings (TTM)

-146.3M

Earnings Growth (Yr)

-9.48%

Earnings Growth (Qtr)

10.7%

Breaking Down KPTI Revenue

Last 7 days

5.1%

Last 30 days

-6.4%

Last 90 days

-32.4%

Trailing 12 Months

-51.2%

How does KPTI drawdown profile look like?

KPTI Financial Health

Current Ratio

3.04

KPTI Investor Care

Shares Dilution (1Y)

3.25%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024140.5M000
2023148.1M146.0M145.9M146.0M
2022234.2M251.3M249.8M157.1M
2021113.2M102.3M118.7M209.8M
202058.9M82.9M91.1M108.1M
201933.0M35.6M38.3M40.9M
201816.5M31.4M31.7M30.3M
2017222.0K567.8K1.3M1.6M
20160309.0K207.0K179.0K
20150208.0K262.0K266.0K
2014325.0K213.0K234.0K229.0K
2013833.0K433.0K399.0K387.0K
2012272.5K393.0K513.5K634.0K
2011000152.0K

Tracking the Latest Insider Buys and Sells of Karyopharm Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 07, 2024
pakianathan deepika
sold
-220,133
0.9507
-231,548
-
Jun 06, 2024
pakianathan deepika
sold
-116,415
0.9828
-118,452
-
Jun 05, 2024
pakianathan deepika
sold
-448,480
0.9582
-468,044
-
Jun 04, 2024
paulson richard a.
sold
-3,556
0.99
-3,592
president and ceo
Jun 04, 2024
pakianathan deepika
sold
-324,704
0.9521
-341,040
-
Jun 04, 2024
mason michael
sold
-645
0.99
-652
evp, cfo & treasurer
Jun 03, 2024
pakianathan deepika
sold
-360,997
1.0007
-360,744
-
May 31, 2024
pakianathan deepika
sold
-194,992
0.954
-204,394
-
May 06, 2024
paulson richard a.
sold
-4,040
1.13
-3,576
president and ceo
Apr 22, 2024
rangwala reshma
sold
-7,943
1.17
-6,789
evp & chief medical officer

1–10 of 50

Which funds bought or sold KPTI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-9,000
-
-%
May 17, 2024
Ikarian Capital, LLC
added
2.34
272,126
618,126
0.07%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
1,069
17,194
-%
May 16, 2024
Colony Group, LLC
new
-
50,000
50,000
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-37.69
20,919
259,192
-%
May 15, 2024
TWO SIGMA SECURITIES, LLC
reduced
-47.88
-1,528
15,414
-%
May 15, 2024
Voya Investment Management LLC
reduced
-14.67
19,259
58,591
-%
May 15, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
reduced
-34.54
35,727
286,145
0.01%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
reduced
-78.96
-327,395
189,997
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
sold off
-100
-54,668
-
-%

1–10 of 40

Are Funds Buying or Selling KPTI?

Are funds buying KPTI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KPTI
No. of Funds

Unveiling Karyopharm Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 23, 2024
j. wood capital advisors llc
5.5%
6,872,027
SC 13G
Feb 14, 2024
avidity partners management lp
9.5%
11,188,743
SC 13G/A
Feb 14, 2024
palo alto investors lp
4.45%
5,102,193
SC 13G/A
Feb 13, 2024
vanguard group inc
7.60%
8,710,158
SC 13G
Feb 12, 2024
rubric capital management lp
0%
0
SC 13G/A
Jan 25, 2024
blackrock inc.
8.8%
10,071,677
SC 13G/A
Jan 22, 2024
state street corp
1.79%
2,053,773
SC 13G/A
Jul 10, 2023
state street corp
1.94%
2,212,367
SC 13G/A
Feb 14, 2023
chione ltd
3.9%
4,400,000
SC 13G/A
Feb 14, 2023
palo alto investors lp
5.00%
5,655,676
SC 13G/A

Recent SEC filings of Karyopharm Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 07, 2024
EFFECT
EFFECT
Jun 07, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
May 31, 2024
8-K
Current Report
May 30, 2024
4
Insider Trading
May 30, 2024
4
Insider Trading
May 30, 2024
4
Insider Trading
May 30, 2024
4
Insider Trading

Peers (Alternatives to Karyopharm Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Karyopharm Therapeutics Inc News

Latest updates
Defense World17 hours ago
The Motley Fool08 May 202407:00 am

Karyopharm Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-1.8%33,126,00033,747,00036,009,00037,579,00038,698,00033,580,00036,145,00039,679,00047,670,000126,269,00037,689,00022,601,00023,260,00035,100,00021,333,00033,514,00018,138,00018,096,00013,149,0009,493,0004,849,500
Operating Expenses-6.5%66,885,00071,555,00067,269,00067,152,00069,597,00067,449,00066,984,00082,587,00082,256,00079,307,00081,501,00071,649,00075,633,00072,166,00068,442,00073,833,00065,494,00061,362,00052,550,00051,179,00065,077,000
  S&GA Expenses-3.7%29,549,00030,688,00030,805,00034,481,00035,907,00034,649,00034,645,00037,339,00038,768,00034,562,00035,104,00036,530,00037,650,00033,929,00030,967,00030,843,00030,678,00028,389,00025,267,00024,662,00027,103,000
  R&D Expenses-10.0%35,425,00039,381,00035,553,00031,477,00032,339,00030,932,00031,359,00044,309,00042,062,00044,003,00045,808,00033,981,00037,050,00037,185,00037,037,00042,594,00033,997,00031,579,00026,270,00026,517,00037,974,000
EBITDA Margin-6.9%-0.87-0.81-0.79-0.80-0.90-0.89-0.24-0.29-0.34-0.46-1.51-1.79---------
Interest Expenses-5.2%5,884,0006,208,0006,073,0005,784,0005,758,0005,885,0006,114,0006,313,0006,684,0007,940,0008,010,0005,001,0005,095,0007,072,0006,801,0006,758,0006,509,0006,467,0003,093,0003,089,0002,998,000
Income Taxes-33.6%71,000107,00012,000127,00054,000104,00045,000121,000130,000-89,000106,000134,000149,00062,00044,000137,00066,0002,00020,0008,00010,000
Earnings Before Taxes10.6%-37,291,000-41,707,000-34,494,000-32,503,000-34,072,000-38,433,000-36,279,000-48,941,000-41,269,00038,599,000-51,706,000-53,448,000-57,265,000-43,359,000-53,451,000-46,289,000-52,865,000-48,645,000-41,347,000-43,407,000-66,151,000
EBT Margin-6.3%-1.04-0.98-0.96-0.97-1.06-1.05-0.35-0.41-0.46-0.59-1.73-2.03---------
Net Income10.7%-37,362,000-41,837,000-34,506,000-32,630,000-34,126,000-38,506,000-36,324,000-49,062,000-41,399,00038,720,000-51,812,000-53,582,000-57,414,000-43,421,000-53,495,000-46,426,000-52,931,000-48,647,000-41,367,000-43,415,000-66,161,000
Net Income Margin-6.3%-1.04-0.98-0.96-0.97-1.07-1.05-0.35-0.41-0.46-0.59-1.74-2.03---------
Free Cashflow-136.3%-43,920,000-18,585,000-29,530,000-25,698,000-18,910,000-26,843,000-28,409,000-35,144,000-59,276,00025,268,000-23,960,000-55,748,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-15.0%204240270298326358231256294305254287275313338380416295298238287
  Current Assets-15.2%198234263291319350223242277276242274256277285318371279281223271
    Cash Equivalents-41.4%31.0052.0044.0081.0084.0013771.0082.0015319013714188.0089.0082.0010320213116876.0084.00
  Inventory-9.0%3.003.003.004.004.004.004.003.004.004.004.004.003.003.002.002.001.000.000.00--
  Net PPE18.6%1.001.001.001.001.001.001.001.002.002.002.002.002.002.002.003.003.003.003.003.004.00
Liabilities-0.9%373377370369371375372373377385380370315263254250250245238156166
  Current Liabilities-6.0%65.0069.0062.0059.0062.0066.0062.0063.0066.0074.0069.0058.0062.0060.0053.0051.0050.0046.0039.0032.0044.00
Shareholder's Equity-24.0%-168-136---45.17-16.66-------51.0084.0013016650.0060.0082.00121
  Retained Earnings-2.5%-1,524-1,487-1,445-1,410-1,378-1,343-1,305-1,269-1,220-1,178-1,217-1,165-1,111-15.00-1,026-972-926-873-824-783-739
  Additional Paid-In Capital0.4%1,3561,3511,3461,3401,3331,3281,1661,1531,1371,0991,0911,0821,0721,1201,1091,1021,093923885866861
Shares Outstanding1.3%11611511511411311380.0079.0078.0075.0075.0075.00---------
Float----201---351---739---1,320---344-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-135.3%-43,725-18,585-29,530-25,698-18,910-26,843-28,370-35,144-59,19725,475-23,955-55,748-52,888-30,634-44,312-40,277-45,011-39,489-36,506-48,204-66,623
  Share Based Compensation-4.1%4,9705,1825,0786,0605,3896,1736,79715,0937,3366,8697,4208,1357,3596,3146,5136,4285,1523,5493,7194,1163,907
Cashflow From Investing-18.3%21,94026,843-7,68521,170-32,388-65,29811,673-36,596-14,03530,77021,42646,45843,18631,39721,431-60,034-46,479-33,51940,17539,80331,991
Cashflow From Financing-100.0%-264-860-155,8435,7991,31330,78389616.0062,06010,6763,9681,2402,046164,82934,93688,822395152
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

KPTI Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Revenue from contract with customer, license and other revenue$ 33,126$ 38,698
Operating expenses:  
Research and development35,42532,339
Selling, general and administrative29,54935,907
Total operating expenses66,88569,597
Loss from operations(33,759)(30,899)
Other income (expense):  
Interest income2,1562,849
Interest expense(5,884)(5,758)
Other income (expense), net196(264)
Total other expense, net(3,532)(3,173)
Loss before income taxes(37,291)(34,072)
Income tax provision(71)(54)
Net loss$ (37,362)$ (34,126)
Net loss per share-basic$ (0.32)$ (0.30)
Net loss per share-diluted$ (0.32)$ (0.30)
Weighted-average number of common shares outstanding used to compute net loss per share-basic115,454,000113,481,000
Weighted-average number of common shares outstanding used to compute net loss per share-diluted115,454,000113,481,000
Product [Member]  
Revenues:  
Revenue from contract with customer, license and other revenue$ 26,006$ 28,288
Operating expenses:  
Cost of sales1,9111,351
License and Other [Member]  
Revenues:  
Revenue from contract with customer, license and other revenue$ 7,120$ 10,410

KPTI Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 30,628$ 52,231
Investments117,950139,212
Accounts receivable, net31,08226,962
Inventory2,7693,043
Prepaid expenses and other current assets15,47811,813
Restricted cash459660
Total current assets198,366233,921
Property and equipment, net719606
Operating lease right-of-use assets3,7354,276
Restricted cash304301
Other assets1,3341,334
Total assets204,458240,438
Current liabilities:  
Accounts payable5,0283,123
Accrued expenses54,85161,394
Operating lease liabilities3,4253,308
Other current liabilities2,0371,654
Total current liabilities65,34169,479
Convertible senior notes171,127170,919
Deferred royalty obligation132,479132,479
Operating lease liabilities, net of current portion1,8842,789
Other liabilities2,582978
Total liabilities373,413376,644
Stockholders' deficit  
Preferred stock, $0.0001 par value; 5,000 shares authorized; none issued and outstanding00
Common stock $0.0001 par value; 400,000 shares authorized; 116,457 and 114,915 shares issued and outstanding at March 31,2024 and December 31,2023, respectively1212
Additional paid-in capital1,355,9511,350,981
Accumulated other comprehensive loss(518)(161)
Accumulated deficit(1,524,400)(1,487,038)
Total stockholders' deficit(168,955)(136,206)
Total liabilities and stockholders' deficit$ 204,458$ 240,438
KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
 CEO
 WEBSITEkaryopharm.com
 INDUSTRYBiotechnology
 EMPLOYEES385

Karyopharm Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Karyopharm Therapeutics Inc? What does KPTI stand for in stocks?

KPTI is the stock ticker symbol of Karyopharm Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Karyopharm Therapeutics Inc (KPTI)?

As of Thu Jun 13 2024, market cap of Karyopharm Therapeutics Inc is 120.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KPTI stock?

You can check KPTI's fair value in chart for subscribers.

What is the fair value of KPTI stock?

You can check KPTI's fair value in chart for subscribers. The fair value of Karyopharm Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Karyopharm Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KPTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Karyopharm Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KPTI is over valued or under valued. Whether Karyopharm Therapeutics Inc is cheap or expensive depends on the assumptions which impact Karyopharm Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KPTI.

What is Karyopharm Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, KPTI's PE ratio (Price to Earnings) is -0.82 and Price to Sales (PS) ratio is 0.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KPTI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Karyopharm Therapeutics Inc's stock?

In the past 10 years, Karyopharm Therapeutics Inc has provided -0.309 (multiply by 100 for percentage) rate of return.